Investor FAQs

Investor FAQs

Find quick answers to frequently asked questions about investing in BioLife Solutions.

 

Where is BioLife Solutions’ common stock traded, and what is the ticker symbol?

BioLife Solutions’ common stock is traded on the NASDAQ Global Market under the symbol BLFS.

When was BioLife Solutions incorporated, and where is it headquartered?

BioLife Solutions was incorporated in 1987 and is headquartered in Bothell, Washington, USA.

What does BioLife Solutions do?

BioLife Solutions develops and supplies biopreservation media, automated cell processing systems, and cryogenic storage solutions that enable cell and gene therapy developers to safely manufacture, store, and deliver advanced therapies. Our tools reduce variability, safeguard cell function, and accelerate commercialization.

Who are BioLife Solutions’ customers?

Our customers include cell and gene therapy developers, academic institutions, contract development and manufacturing organizations (CDMOs), and biopharma companies.

How can I obtain copies of BioLife Solutions’ financial documents such as SEC filings, annual reports, and quarterly results?

You can access our SEC filings, annual reports, quarterly results, and earnings presentations directly on our Investor Relations site.

Does BioLife Solutions pay dividends?

BioLife Solutions does not pay dividends. The company intends to retain earnings to fund continued growth and expansion.

Who makes up BioLife Solutions’ management team and Board of Directors?

Information about our executive leadership, advisory boards, and Board of Directors is available on the [Leadership page] of our website.

Who is the company’s independent registered public accounting firm?

BioLife Solutions’ independent registered public accounting firm is BDO USA, LLP.

Who is the company’s transfer agent, and how can I contact them?

Our transfer agent is Broadridge Corporate Issuer Solutions, Inc. Shareholders may contact Broadridge for assistance with changes of address, stock transfer, lost certificates, or account consolidation. Broadridge Corporate Issuer Solutions, Inc. | P.O. Box 1342, Brentwood, New York 11717 | (877) 830 - 4936 | shareholder@broadridge.com

How do I contact BioLife Solutions Investor Relations?

For investor inquiries, please contact either Troy Wichterman, Chief Financial Officer (425) 402-1400 twichterman@biolifesolutions.com or Alliance Advisors IR Jody Cain (310) 691-7100 jcain@allianceadvisors.com

We believe the promise of cell and gene therapies starts with the integrity of a single cell

Advancing the future of cell and gene therapy

The human body can heal itself. Cell and gene therapies are designed to augment the patient’s ability to fight disease but only if the living cells behind those therapies remain viable and functional throughout the production processes. At BioLife Solutions, our mission is to protect the integrity of cells and provide trusted tools, services, and expertise that can enable our customers to advance the development and delivery of cell and gene therapies. We believe the future of cell and gene therapies hinges on the integrity of every single cell and we are here to protect that promise.

We understand the technical demands of bioprocessing in this field, and our advanced biopreservation expertise, cell culture optimization products, innovative storage systems, and closed-system manufacturing solutions are designed to enhance process efficiency, maintain cellular viability, and ensure reproducibility at every stage. Whether scaling up from R&D, navigating clinical trials or optimizing cryopreservation protocols for commercial production, we provide the tools and experience to streamline your workflow and safeguard your therapies.

Work with experts who understand your biopreservation challenges

Notch-Right-25px
Notch-Bottom-25px

Collaborative and comprehensive CDMO support

At BioLife Solutions, we partner with leading contract development and manufacturing organizations (CDMOs) to enhance their biopreservation and cell processing capabilities. By providing advanced tools, regulatory support, and process optimization strategies, we empower CDMOs to better serve therapy developers, ensuring quality, consistency, and scalability in cell therapy manufacturing.

Regulatory
readiness

Navigating the complex regulatory landscape of cell and gene therapy requires a proactive approach. BioLife Solutions offers experienced regulatory support to help prepare your biopreservation and cell processing methods to meet global standards. From IND and BLA submissions to compliance with GMP, FDA, and EMA guidelines, our solutions help streamline approval pathways.

Notch-Left-25px
Notch-Bottom-25px

STORE

CellSeal®
CryoCase

Alleviate CGT container challenges like fracture risk, bag burping or high rates of particulates

Notch-Right-25px
Notch-Bottom-25px

Data-driven
decision making

Stay ahead with our comprehensive Evidence Library, a curated collection of scientific publications, white papers, and case studies demonstrating the efficacy of BioLife Solutions’ technologies. Access peer-reviewed research, real-world application data, and expert insights to support your bioprocessing and regulatory strategies.

Insights

May 21, 2025

Designing the Ideal Cryostorage Container for CGT

April 18, 2025

The Cell Summit ’25: A Must-Attend Event for Innovators in Cell & Gene Therapy

March 27, 2025

Optimizing Biopreservation Strategies for Apheresis-Derived Cells in Immunotherapeutic Applications

February 19, 2025

How to prepare early for regulatory submissions from IND to BLA

Preserve, protect and expand cell performance

Mastering
Biopreservation

Ensure Regulatory Submission Readiness

Automate & Close
CGT Processes

Protect & Expand
Cell Performance